Company intelligence / Profile preview

Alterome Therapeutics

San Diego, California, United Statesalterome.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Alterome is developing first-in-class small molecules targeting cancer's most evasive targets including AKT and KRAS. The company plans to bring two programs to the clinic within the next year (as of their 2023 funding announcement).

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

ALTA-2618

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Alterome Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alterome Therapeutics.

Explore the full profile